TICKERNERD
Menu
MDLNHealthcare · Medical Instruments & Supplies

MDLN Stock Forecast: Medline, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$36
+0.64% on the day

The 27 Wall Street analysts covering Medline, Inc. hold a median 12-month price target of $45 — +25.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$48.1B
Ticker Nerd rank
21 / 100
Median analyst target
$45
Analysts covering
27
Free cash flow$604.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
+10.2%
YTD
−14.5%
From high
−28.1%
From low
+13.6%
$32
$50
Range since 17 Dec 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

MDLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medline, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
67
Issuance
62
Revisions
57
Quality
43
Value
41
Growth
32
Momentum
6
Size
5
Volatility
1

Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MDLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Dec 2025Adjusted close, US dollars
$30$35$40$45$50$55Jan 26Apr 26Jul 26Oct 26MDLNHigh $55Median $45Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
23 Buy4 Hold0 Sell
Low $34Median $45High $55

The green dot is the last close — the median target sits +25.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 9 moved it down.

DateFirmActionRatingTarget
9 Oct 2026BarclaysMaintainsOverweight$45 → $43
25 Sept 2026UBSMaintainsBuy—
25 Sept 2026UBSMaintainsBuy$45 → $43
27 Aug 2026BTIGReiteratesBuy—
27 Aug 2026BTIGReiteratesBuy$55
12 Aug 2026JP MorganMaintainsOverweight—
12 Aug 2026JP MorganMaintainsOverweight$53 → $46
11 Aug 2026Tigress FinancialMaintainsBuy$62 → $55
11 Aug 2026Tigress FinancialMaintainsBuy—
11 Aug 2026Wells FargoMaintainsEqual-Weight$45 → $34
11 Aug 2026Wells FargoMaintainsEqual-Weight—
10 Aug 2026TD CowenMaintainsBuy$53 → $45
10 Aug 2026TD CowenMaintainsBuy—
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026Evercore ISI GroupMaintainsOutperform$48 → $39
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026RBC CapitalMaintainsOutperform$53 → $46
6 Aug 2026StifelMaintainsBuy—
6 Aug 2026StifelMaintainsBuy$50 → $45
6 Aug 2026Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MDLN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

MDLN vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26MDLNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MDLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.5%
Analysts raising
0
Analysts cutting
4
Fundamentals

Medline, Inc. (MDLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
89.4×

Cheaper than 8% of US stocks

Price / sales
1.6×

Cheaper than 57% of US stocks

Price / book
2.7×

Cheaper than 34% of US stocks

EV / EBITDA
19.4×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
11.6%

Higher than 56% of US stocks

Earnings growth (YoY)
−82.0%

Higher than 5% of US stocks

Gross margin
28.8%

Higher than 32% of US stocks

Operating margin
0.8%

Higher than 47% of US stocks

Net margin
2.3%

Higher than 53% of US stocks

Returns & dividend
Return on equity
4.9%

Higher than 53% of US stocks

Return on assets
2.5%

Higher than 62% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Medline, Inc. (MDLN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Medline, Inc. has a market value of $48.1B and an enterprise value of $48.8B.

  • Diluted earnings per share, trailing twelve months: $0.40.

  • Shares outstanding: 877.0M.

  • Trailing P/E: 89.4×; forward P/E: 22.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Medline, Inc. employs 45,000 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

MDLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MDLNMedline, Inc.$48.1B
21
BDXBecton, Dickinson & Co.$52.0B
94
RMDResMed, Inc.$34.3B
74
ALCAlcon AG$32.0B
—
WSTWest Pharmaceutical Services, Inc.$27.0B
93
SOLVSolventum Corp.$15.1B
92
ISRGIntuitive Surgical, Inc.$148.5B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medline, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDLN news & analysis

MDLN Stock Alert: Medline Product Quality Issues and Subsequent 13% Stock Drop Trigger Securities Fraud Investigation for Investors

PRNewsWire · 13 Oct 2026negative

Bleichmar Fonti & Auld LLP announced an investigation into Medline Inc. over potential securities fraud related to statements about manufacturing and product quality, following significant stock drops.

Why it matters — The investigation and reported stock decline may be relevant to investors monitoring Medline’s product-quality disclosures and securities matters.

Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care

PRNewsWire · 12 Oct 2026positive

Medline announced an enhanced TrackPoint inventory management and patient item usage solution for long-term care and inpatient hospice providers. The update combines real-time inventory tracking with PointClickCare integration to help capture patient-level usage and improve visibility across locations.

Why it matters — The launch highlights an updated Medline offering intended to streamline supply management for post-acute care providers.

MDLN Securities Alert: Lose Money on Your Medline Investment? BFA Law Notifies Investors of the Ongoing Securities Fraud Investigation over Product Quality Issues

GlobeNewsWire · 9 Oct 2026negative

Bleichmar Fonti & Auld LLP announced an investigation into Medline Inc. for potential securities fraud following significant stock drops. The announcement describes the investigation as related to product quality issues.

Why it matters — MDLN investors may follow the investigation and its potential implications for the company.

FAQ

Frequently asked questions about MDLN stock

What is the MDLN stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Medline, Inc. have a median 12-month price target of $45, with estimates ranging from $34 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDLN stock a buy right now?

Of the 27 analysts covering Medline, Inc., 23 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medline, Inc. 21 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDLN?

As at 14 Oct 2026, Medline, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).

Will MDLN stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +25.2% from the last close, and Ticker Nerd's factor model ranks Medline, Inc. 21 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDLN stock forecast for 2030?

No analyst covering Medline, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $55 over the next 12 months.

What does Medline, Inc. do?

Medline Inc. Class A Common Stock represents ownership in Medline Inc., a healthcare company focused on medical-surgical products and supply chain solutions.

What is the latest news on MDLN?

The most recent item we track (PRNewsWire, 13 Oct 2026): "MDLN Stock Alert: Medline Product Quality Issues and Subsequent 13% Stock Drop Trigger Securities Fraud Investigation for Investors". Bleichmar Fonti & Auld LLP announced an investigation into Medline Inc. over potential securities fraud related to statements about manufacturing and product quality, following significant stock drops.

Company

About Medline, Inc.

Medline Inc. Class A Common Stock represents ownership in Medline Inc., a healthcare company focused on medical-surgical products and supply chain solutions. Medline serves hospitals, ambulatory surgery centers, physician offices, post-acute facilities, and nursing homes through a broad portfolio of products and services used across everyday clinical care. Its business is organized around product manufacturing and procurement, as well as logistics and distribution support for healthcare customers. The company also provides tailored supply chain solutions designed to help healthcare providers manage sourcing, inventory, and delivery across multiple care settings. Medline’s role in the market is centered on supporting the operational needs of the healthcare industry with essential supplies and integrated services.

CEO Mr. James M. Boyle · 45,000 employees · United States · https://www.medline.com